Focus on Adolescent Use of Club Drugs and “Other” Substances

Janet F. Williams; Leslie H. Lundahl

doi:10.1016/j.pcl.2019.08.013

Focus on Adolescent Use of Club Drugs and “Other” Substances

Janet F. Williams, Leslie H. Lundahl

Department of Pediatrics

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Club drugs and “other” abusable substances are briefly overviewed as a reminder about the wide variety of known and unknown substances used by adolescents, the high potential for direct and interactive substance use effects to manifest acutely and chronically, and the vigilance needed to anticipate and recognize the new effects and drug-drug interactions arising as novel substances continue to be custom “designed,” manufactured, and marketed to meet substance use trends. This article discusses dextromethorphan, flunitrazepam (Rohypnol), gamma-hydroxybutyrate, inhalants, ketamine, lysergic acid diethylamide, methylenedioxymethamphetamine, phencyclidine, Salvia divinorum (salvia), synthetic cannabinoids, and synthetic cathinones (bath salts).

Original language	English (US)
Pages (from-to)	1121-1134
Number of pages	14
Journal	Pediatric Clinics of North America
Volume	66
Issue number	6
DOIs	https://doi.org/10.1016/j.pcl.2019.08.013
State	Published - Dec 2019

Keywords

Adolescents
Club drugs
Designer drugs
Hallucinogens
Inhalants
OTC substances
SBIRT

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/j.pcl.2019.08.013

Cite this

@article{28490cb0106a441c8c03513582d41a46,

title = "Focus on Adolescent Use of Club Drugs and “Other” Substances",

abstract = "Club drugs and “other” abusable substances are briefly overviewed as a reminder about the wide variety of known and unknown substances used by adolescents, the high potential for direct and interactive substance use effects to manifest acutely and chronically, and the vigilance needed to anticipate and recognize the new effects and drug-drug interactions arising as novel substances continue to be custom “designed,” manufactured, and marketed to meet substance use trends. This article discusses dextromethorphan, flunitrazepam (Rohypnol), gamma-hydroxybutyrate, inhalants, ketamine, lysergic acid diethylamide, methylenedioxymethamphetamine, phencyclidine, Salvia divinorum (salvia), synthetic cannabinoids, and synthetic cathinones (bath salts).",

keywords = "Adolescents, Club drugs, Designer drugs, Hallucinogens, Inhalants, OTC substances, SBIRT",

author = "Williams, {Janet F.} and Lundahl, {Leslie H.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = dec,

doi = "10.1016/j.pcl.2019.08.013",

language = "English (US)",

volume = "66",

pages = "1121--1134",

journal = "Pediatric Clinics of North America",

issn = "0031-3955",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Focus on Adolescent Use of Club Drugs and “Other” Substances

AU - Williams, Janet F.

AU - Lundahl, Leslie H.

PY - 2019/12

Y1 - 2019/12

N2 - Club drugs and “other” abusable substances are briefly overviewed as a reminder about the wide variety of known and unknown substances used by adolescents, the high potential for direct and interactive substance use effects to manifest acutely and chronically, and the vigilance needed to anticipate and recognize the new effects and drug-drug interactions arising as novel substances continue to be custom “designed,” manufactured, and marketed to meet substance use trends. This article discusses dextromethorphan, flunitrazepam (Rohypnol), gamma-hydroxybutyrate, inhalants, ketamine, lysergic acid diethylamide, methylenedioxymethamphetamine, phencyclidine, Salvia divinorum (salvia), synthetic cannabinoids, and synthetic cathinones (bath salts).

AB - Club drugs and “other” abusable substances are briefly overviewed as a reminder about the wide variety of known and unknown substances used by adolescents, the high potential for direct and interactive substance use effects to manifest acutely and chronically, and the vigilance needed to anticipate and recognize the new effects and drug-drug interactions arising as novel substances continue to be custom “designed,” manufactured, and marketed to meet substance use trends. This article discusses dextromethorphan, flunitrazepam (Rohypnol), gamma-hydroxybutyrate, inhalants, ketamine, lysergic acid diethylamide, methylenedioxymethamphetamine, phencyclidine, Salvia divinorum (salvia), synthetic cannabinoids, and synthetic cathinones (bath salts).

KW - Adolescents

KW - Club drugs

KW - Designer drugs

KW - Hallucinogens

KW - Inhalants

KW - OTC substances

KW - SBIRT

UR - http://www.scopus.com/inward/record.url?scp=85074187942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074187942&partnerID=8YFLogxK

U2 - 10.1016/j.pcl.2019.08.013

DO - 10.1016/j.pcl.2019.08.013

M3 - Review article

C2 - 31679602

AN - SCOPUS:85074187942

SN - 0031-3955

VL - 66

SP - 1121

EP - 1134

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

IS - 6

ER -

Focus on Adolescent Use of Club Drugs and “Other” Substances

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this